Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cureus|February 23, 2023
A Novel Prognostic Index for Metastatic Colon Cancer: The Prognostic Immune Nutritional IndexErkan Kayikcioglu, Gokce Iscan
Medicine|February 23, 2023
The role of claudin 18.2 and HER-2 in pancreatic cancer outcomesErkan Kayikcioglu, Ramazan Oğuz Yüceer
Surgical Oncology|April 30, 2024
Machine learning for predicting colon cancer recurrenceErkan Kayikcioglu, Arif Hakan Onder, Burcu Bacak, et al.
World Journal of Gastrointestinal Oncology|March 13, 2023
Prognostic value of claudin 18.2 expression in gastric adenocarcinomaErkan Kayikcioglu, Ramazan Oğuz Yüceer, Bulent Cetin, et al.
Diagnostics (Basel, Switzerland)|December 17, 2024
The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal CarcinomaAsim Armagan Aydin, Ramazan Oguz Yuceer, Senay Yildirim, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|September 4, 2023
Prognostic value of computed tomography associated body composition measurement changes in metastatic colorectal cancer patientsZekai Emre Sevgilioglu, Sehnaz Evrimler, Gokce Iscan, et al.
Cureus|November 11, 2024
Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic CancerAsim Armagan Aydin, Erkan Kayikcioglu, Ahmet Unlu, et al.
Expert Review of Anticancer Therapy|August 29, 2025
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocolAsim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, et al.
Journal of Chemotherapy (Florence, Italy)|March 18, 2024
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) studyHasan Cagri Yildirim, Caner Kapar, Baris Koksal, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Pageof 2